← All indications
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
Drugs by status
Approved for this indication (7)
Phase 4 trials (10)
Phase 3 trials (26)
- fludarabine
- temsirolimus
- autologous hematopoietic stem cells
- sargramostim
- methotrexate
- stem cells
- autologous umbilical cord blood
- sirolimus
- cirmtuzumab
- allogeneic adipose derived mesenchymal stem cell
- venetoclax
- melphalan
- parsaclisib
- fludeoxyglucose f-18
- mycophenolate
- interferon alpha-2b
- bendamustine
- allogeneic hematopoietic stem cells
- ublituximab
- bgb-11417
- cd19 car-t cells
- umbralisib
- carmustine
- cyclosporine
- allogeneic bone marrow
- orelabrutinib
Phase 2 trials (159)
- eltrombopag
- antineoplaston a10
- allogeneic cytomegalovirus-specific cytotoxic t lymphocytes
- brentuximab vedotin
- im19 car-t cells
- pcar-019
- veliparib
- cladribine
- leuprolide
- ms-553
- Gusacitinib
- cpg-activated, autologous tumor vaccine
- autologous mononuclear stem cell
- pacritinib
- ixabepilone
- lp-168
- bgb-10188
- allopurinol
- cd3+ teff cells
- everolimus
- carfilzomib
- abexinostat
- Epcoritamab
- ibritumomab tiuxetan
- atorvastatin
- allogeneic stem cells
- ofatumumab
- axicabtagene ciloleucel
- nemtabrutinib
- entospletinib
- +129 more
Phase 1 trials (118)
- lv20.19 car t cells
- depatuxizumab mafodotin
- bcl201
- syncar-001
- voruciclib
- ltz-301
- methoxyamine
- iks03
- ispinesib
- repaglinide
- PSB102
- utomilumab
- ly3214996
- cd22 car-t cells
- bms 387032
- cdx-301
- egfrt/19-28z/4-1bbl car t cells
- y90 dota-biotin
- swi019
- magrolimab
- amg 562
- autologous lymphocytes
- bcl-2 antisense oligonucleotide
- multi-peptide cmv-modified vaccinia ankara vaccine
- allogeneic gamma-delta t cells
- triapine
- morab-004
- ramucirumab
- anti-cd19/cd20/cd22 car t-cells
- onm-501
- +88 more
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (39)
- Cephalon
- BeOne Medicines
- Sponsor GmbH
- Teva
- TG Therapeutics, Inc.
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- ECOG-ACRIN Cancer Research Group
- European Mantle Cell Lymphoma Network
- German Low Grade Lymphoma Study Group
- University of Washington
- French Innovative Leukemia Organisation
- Gruppo Italiano Studio Linfomi
- Medical College of Wisconsin
- Swiss Group for Clinical Cancer Research
- The Lymphoma Academic Research Organisation
- Justus Liebig University Giessen
- University of Groningen
- University of Heidelberg
- University of Plymouth
- Columbia University
- Nordic Lymphoma Group
- Loxo Oncology
- Humanitas University
- The University of Hong Kong
- European Organisation for Research and Treatment of Cancer
- The Lymphoma Study Association
- Janssen Pharmaceutica NV
- AZ Sint-Jan
- +9 more
Organization Involved with Phase 2 Indications (201)
- S*BIO
- Incyte
- Abbott
- AbbVie
- Spectrum Pharmaceuticals
- Corixa
- Seattle Genetics
- Takeda
- Bristol-Myers Squibb
- Amgen
- Onyx
- Genmab
- Roche
- Gilead Sciences
- AstraZeneca
- Merck
- Merck Serono
- Eli Lilly
- Genentech
- Merck KGaA
- Genzyme
- Biogen
- Wyeth
- Novartis
- Aprea Therapeutics AB
- Asana BioSciences
- Ascenta Therapeutics
- Bayer
- CABYC
- Centaurus Biopharma Co., Ltd.
- +171 more
Organization Involved with Phase 1 Indications (42)
- ADC Therapeutics SARL
- Zhejiang DTRM Biopharma
- Medarex
- Immunomedics
- Morphotek
- Medivation
- Sanofi
- Arno Therapeutics
- ArQule
- Bio-Path Holdings, Inc.
- Celldex Therapeutics
- Juno Therapeutics, Inc.
- Karyopharm Therapeutics Inc
- Parexel
- Triphase Research and Development Corporation
- Epizyme, Inc.
- University of Pittsburgh
- Augusta University
- California Institute for Biomedical Research
- Cancer and Leukemia Group B (CALGB)
- Rhode Island Hospital
- Wake Forest University
- Soochow University
- University of California, Davis
- University of California, Los Angeles
- University of Colorado, Denver
- MEI Pharma
- The Parker Institute
- University of North Carolina at Chapel Hill
- Washington University in St. Louis
- +12 more
Organization Involved with Other Experimental Indications (2)